Research programme: cannabinoid based therapeutics - Therapix Biosciences

Drug Profile

Research programme: cannabinoid based therapeutics - Therapix Biosciences

Alternative Names: palmitoylethanolamide; palmitoylethanolamide combination therapies - Therapix

Latest Information Update: 24 Dec 2016

Price : $50

At a glance

  • Originator Dekel Pharmaceuticals
  • Developer Therapix Biosciences
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cognition disorders
  • Research Inflammation; Pain

Most Recent Events

  • 31 Oct 2016 Preclinical trials in Cognition disorders in North America (unspecified route)
  • 31 Oct 2016 Therapix Biosciences plans a clinical trial for Cognitive impairments in North America
  • 14 Jan 2015 Early research in Inflammation in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top